REVVITY, INC. RVTY

Technology SIC 3826 - Laboratory Analytical Instruments NAICS Manufacturing › Computer and Electronic Product Manufacturing › Navigational, Measuring, Electromedical, and Control Instruments Manufacturing › Analytical Laboratory Instrument Manufacturing derived NYSE

We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

Our headquarters are in Waltham, Massachusetts, and we market our products and services in more than 160 countries. As of December 28, 2025, we employed approximately 11,000 employees. Our common stock is listed on the New York Stock Exchange under the symbol "RVTY" and we are a component of the S&P 500 Index.

Last close 158.77 2026-10-23
Market cap $17.72B 2026-07-05 share count
52-week range 81.22 - 166.25

Valuation FY2025 figures against the last close

P/S6.2x
P/E76.7x
P/FCF34.8x
EV/EBITDA26.3x
Dividend yield0.2%
Diluted EPS2.07

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • Other International
  • China
  • Germany
  • United Kingdom
Revenue by geography, 5 categories over 3 years. The same figures are in the table below. FY2025 United States, FY2025: 1.1B (39.4%) 39% United States Other International, FY2025: 1B (35.0%) 35% Other International China, FY2025: 425.1M (14.9%) 15% China Germany, FY2025: 177.7M (6.2%) 6% Germany United Kingdom, FY2025: 126.8M (4.4%) 4% FY2024 United States, FY2024: 1.1B (39.8%) 40% Other International, FY2024: 931.7M (33.8%) 34% China, FY2024: 450M (16.3%) 16% Germany, FY2024: 162.6M (5.9%) 6% United Kingdom, FY2024: 112.9M (4.1%) 4% FY2023 United States, FY2023: 1.1B (40.6%) 41% Other International, FY2023: 859.9M (31.3%) 31% China, FY2023: 454.4M (16.5%) 17% Germany, FY2023: 193.2M (7.0%) 7% United Kingdom, FY2023: 125.4M (4.6%) 5%
Region FY2025FY2024FY2023
United States $1.13B $1.10B $1.12B
Other International $1.00B $931.7M $859.9M
China $425.1M $450.0M $454.4M
Germany $177.7M $162.6M $193.2M
United Kingdom $126.8M $112.9M $125.4M

As the company reported it, from the “Industry Segment and Geographic Area Information Schedule of Revenue by Geographic Area (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $2.86B$2.76B$2.75B$3.31B$3.83B$2.66B$2.88B$2.78B$2.26B$2.12B
Cost of revenue ———————$1.44B$475.3M$437.4M
Gross profit ———$1.99B$2.43B$2.11B$1.40B$1.34B$1.07B$1.01B
R&D $215.8M$196.8M$216.6M$221.6M$200.3M$146.4M$189.3M$194.0M$139.5M$124.2M
SG&A $991.9M$994.1M$1.02B$1.03B$975.2M$716.5M$815.3M$811.9M$626.0M$590.5M
Operating income $356.6M$346.7M$300.6M$742.7M$1.26B$867.3M$362.0M$323.9M$295.6M$294.6M
Interest expense $92.2M$96.3M$98.8M$104.0M—$49.7M$63.6M$67.0M$43.9M$41.5M
Pre-tax income $268.3M$316.1M$183.0M$651.8M$1.20B$800.1M$237.1M$257.7M$296.7M$244.1M
Income tax $28.4M$33.1M$3.5M$139.2M$314.1M$169.5M$9.4M$20.2M$139.8M$28.4M
Net income $241.2M$270.4M$693.1M$569.2M$943.2M$727.9M$227.6M$237.9M$292.6M$234.3M
EPS, basic 2.072.215.564.518.126.522.062.152.672.14
EPS, diluted 2.072.205.554.508.086.492.042.132.642.12
Shares, diluted (wtd. avg.) 116.6M122.8M124.8M126.4M116.7M112.1M111.5M111.5M110.9M110.3M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $919.9M$1.16B$913.2M$470.7M$619.3M$402.6M$191.9M$166.3M$202.4M$376.6M
Short-term investments —$0$689.9M$0——————
Receivables $744.7M$632.4M$632.8M$612.8M$707.9M$1.16B$725.2M$632.7M$552.3M$425.6M
Inventory $379.5M$367.6M$428.1M$405.5M$425.9M$514.6M$356.9M$338.3M$351.7M$246.8M
Total current assets $2.24B$2.35B$3.00B$3.29B$2.44B$2.24B$1.37B$1.23B$1.20B$1.19B
Property, plant and equipment $479.2M$482.2M$509.7M$482.9M$485.5M$368.3M$318.2M$318.6M$298.1M$145.5M
Goodwill $6.61B$6.46B$6.53B$6.48B$6.63B$2.64B$3.11B$2.95B$3.00B$2.25B
Other intangibles $2.35B$2.64B$3.02B$3.38B$3.82B$1.37B$1.28B$1.20B$1.35B$420.2M
Total assets $12.17B$12.39B$13.56B$14.13B$15.00B$7.96B$6.54B$5.98B$6.09B$4.28B
Accounts payable $185.5M$167.5M$204.1M$272.8M$324.8M$327.3M$235.9M$220.9M$222.1M$168.0M
Short-term debt $588.8M$242.0K$721.9M$470.9M—$380.9M————
Total current liabilities $1.33B$653.1M$1.45B$1.54B$1.21B$1.65B$762.8M$771.6M$950.9M$603.4M
Long-term debt $2.63B$3.15B$3.18B$3.92B$4.98B$1.61B$2.06B$1.88B$1.79B$1.05B
Total liabilities $4.92B$4.73B$5.69B$6.75B$7.86B$4.22B$3.72B$3.39B$3.59B$2.12B
Retained earnings $6.05B$5.85B$5.61B$4.95B$4.42B$3.51B$2.81B$2.60B$2.38B$2.12B
Total equity $7.25B$7.67B$7.87B$7.38B$7.14B$3.74B$2.81B$2.58B$2.50B$2.15B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $582.9M$628.3M$91.3M$679.8M$1.41B$892.2M$363.5M$311.0M$288.5M$350.6M
Depreciation and amortisation $405.3M$427.8M$431.8M$427.0M$311.4M$201.6M$214.0M$180.6M$105.0M$100.0M
Stock-based compensation $22.8M$37.8M$41.4M$51.5M$29.7M$26.9M$31.5M$28.8M$25.4M$17.2M
Capital expenditure $73.5M$86.6M$81.4M$85.6M$86.0M$63.6M$76.3M$93.3M$39.1M$31.7M
Investing cash flow -$17.4M$776.2M$1.31B-$132.9M-$4.11B-$504.5M-$487.6M-$159.9M-$1.27B-$83.9M
Financing cash flow -$857.5M-$1.13B-$947.1M-$661.8M$2.94B-$202.9M-$150.1M-$179.2M$782.2M-$115.0M
Dividends paid $32.8M$34.5M$35.0M$35.3M$32.4M$31.2M$31.1M$31.0M$30.8M$30.8M
Buybacks $820.8M$369.6M$388.9M$80.6M$73.1M$6.9M$6.3M$57.4M$3.8M$151.8M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000031791-26-000012.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 1B 2B 3B 4B Revenue, FY2016: 2.1B Gross profit, FY2016: 1B Net income, FY2016: 234.3M Revenue, FY2017: 2.3B Gross profit, FY2017: 1.1B Net income, FY2017: 292.6M Revenue, FY2018: 2.8B Gross profit, FY2018: 1.3B Net income, FY2018: 237.9M Revenue, FY2019: 2.9B Gross profit, FY2019: 1.4B Net income, FY2019: 227.6M Revenue, FY2020: 2.7B Gross profit, FY2020: 2.1B Net income, FY2020: 727.9M Revenue, FY2021: 3.8B Gross profit, FY2021: 2.4B Net income, FY2021: 943.2M Revenue, FY2022: 3.3B Gross profit, FY2022: 2B Net income, FY2022: 569.2M Revenue, FY2023: 2.8B Net income, FY2023: 693.1M Revenue, FY2024: 2.8B Net income, FY2024: 270.4M Revenue, FY2025: 2.9B Net income, FY2025: 241.2M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $2.12B $2.26B $2.78B $2.88B $2.66B $3.83B $3.31B $2.75B $2.76B $2.86B
Gross profit $1.01B $1.07B $1.34B $1.40B $2.11B $2.43B $1.99B — — —
Net income $234.3M $292.6M $237.9M $227.6M $727.9M $943.2M $569.2M $693.1M $270.4M $241.2M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced Item 2.02
  • Other event Item 8.01
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3826

TickerCompanyMarket capP/ERevenue growth
A AGILENT TECHNOLOGIES, INC. $48.79B 37.9x 6.7%
WAT WATERS CORP /DE/ $44.57B 42.2x 7.0%
ILMN ILLUMINA, INC. $40.68B 49.4x -0.7%
MTD METTLER TOLEDO INTERNATIONAL INC/ $33.47B 39.7x 4.0%
AVTR Avantor, Inc. $11.80B — -3.4%
BIO BIO-RAD LABORATORIES, INC. $9.89B 13.3x 0.7%
TXG 10x Genomics, Inc. $9.30B — 5.2%
BRKR BRUKER CORP $8.74B — 2.1%